iih glp 1 NeuroOp Guru: Stopping GLP-1 therapy may trigger recurrent papilledema in cases | Eye Care Network Idiopathic Intracranial Hypertension After Abrupt
Description
Stage 3 - Ongoing care and dose management
Severe Malnutrition and Dehydration When GI Problems Become Systemic: Chronic inability to eat or keep food down leads to: Dangerous weight loss (beyond intended amount) Vitamin and mineral deficiencies Muscle wasting Weakness and fatigue Electrolyte imbalances (can cause heart problems) Need for IV nutrition (TPN - total parenteral nutrition) Legal Damages: Cost of nutritional support Hospitalizations Lost ability to work Permanent health consequences 5
summarized and analyzed all research on the prevalence of CMD in HFpEF patients, finding a high pooled prevalence of 71% [29]
NYHA = New York Heart Association
Novo Nordisk filed its New Drug Application with the FDA on 18 December 2025, based on data from the REDEFINE 1 trial
